Table 1.

Studies with different basal immunosuppression schedules for patients with hepatocellular carcinoma after liver transplantationv

Ref.	Year	Immunosuppressor type	Evaluated parameters	Recurrence rate	P value
Rodríguez-Perálvarez et al[10]	2013	CNI	Low exposure 1st vs high exposure 1st	27.7% vs 14.7% at 5 yr	0.007
Vivarelli et al[16]	2005	CSA	Low exposure vs high exposure	0% vs 33.3%	< 0.001
Vivarelli et al[14]	2008	TAC	Low exposure vs high exposure	9.1% vs 50%	0.001
Menon et al[21]	2013	SRL and CNIs	SRL vs CNIs	4.9%-12.9% vs 17.3%-38.7%	NA
Cholongitas et al[22]	2014	CNIs and mTORi	CNIs vs mTORi	22% vs 44%	< 0.050

CNI: Calcineurin inhibitors; CsA: Cyclosporine A; TAC: Tacrolimus; SRL: Sirolimus; mTORi: The mammalian target of rapamycin inhibitors; NA: Not analyzed.